Insider Selling: Martine A. Rothblatt Unloads 3,833 Shares of United Therapeutics Corp. Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt unloaded 3,833 shares of the stock on the open market in a transaction dated Thursday, February 20th. The stock was sold at an average price of $103.91, for a total value of $398,287.03. Following the completion of the sale, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $14,547. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 2.17% during mid-day trading on Friday, hitting $103.34. 615,909 shares of the company’s stock traded hands. United Therapeutics Corp. has a one year low of $56.80 and a one year high of $116.65. The stock has a 50-day moving average of $105.5 and a 200-day moving average of $89.78. The company has a market cap of $5.190 billion and a price-to-earnings ratio of 19.19.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $91.07.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.